The body has finite capacity to use BPC-157 for healing, and exceeding that threshold provides no additional benefit while depleting supplies faster
GI effects are the primary concern, primarily nausea, vomiting, diarrhea, and constipation
Keep away from children and keep tightly closed in a cool dry place
pharmacies cannot legally compound them for patient use
Similarly, brands that offer exfoliating treatments or retinoid products may present copper peptide serums as balancing formulas that help maintain skin comfort between stronger treatments
1 Press release, July 3, 2026, ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI 2 Press Release, July 5, 2023, ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing 3 Press Release, July 25, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T2D 4 Press Release, October 15, 2025, ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone Lispro (THDB0206 injection) in people with T1D 5 GMP = Good Manufacturing Practices 6 P ress Release, November 12, 2025, ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong - and Provides an Update on its BioChaperone Platform Adocia Olivier Soula CEO [email protected] +33 (0)4 72 610 610 www.adocia.com Maarc Adocia Press & Investor Relations Bruno Arabian Yasmine Duval Thomas Rolnik [email protected] + 33 (0)6 87 88 47 26 View source version on businesswire.com: The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties
